TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18097109
Drug: Short-course intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course intermittent chemotherapy (2EHRZ 3 /4RH 3 ) thrice weekly for 6 months
Study: 15118032
Drug: Topical glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical glyceryl trinitrate (1.25 mg per twenty-four hours)
Study: 11986765
Drug: Capecitabine (1255
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (1255 mg m(‐2) twice daily, days 1-14)
Study: 11986765
Drug: Paclitaxel (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (175 mg m(‐2))
Study: 9829849
Drug: Prophylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatment initiated until the third year of life (Group 1)
Study: 9829849
Drug: Prophylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatment initiated at age 5 years and above (Group 2)
Study: 9829849
Drug: Repeated joint
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated joint bleeding (>5) prior to prophylactic treatment
Study: 8137517
Drug: Injectable bromocriptine
Normalized name: bromocriptine Injectable Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable bromocriptine 50 mg intramuscularly for 28 days (Group A)
Study: 8137517
Drug: Oral bromocriptine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bromocriptine 7.5 mg daily for 28 days (Group B)
Study: 29225313
Drug: Coffee polyphenols
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coffee polyphenols (CPPs) 297.8 mg daily for 4 weeks
Study: 19339127
Drug: Soy Isoflavones
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy Isoflavones Extract (SIE) 120mg daily
Study: 17302023
Drug: Pillar(R) Palatal
Normalized name: malate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pillar(R) Palatal Implant System
Study: 11376828
Drug: Subcutaneous patch
Normalized name: Patch
DrugBank: Lavender oil (DB14566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous patch electrode
Study: 11376828
Drug: Subcutaneous array
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous array electrode
Study: 3167526
Drug: Nefopam hydrochloride
Normalized name: nefopam hydrochloride
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam hydrochloride (20 mg)
Study: 27894271
Drug: Physical exercise
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical exercise program involving progressive and challenging balance training and neuromuscular and functional training of the lower limbs, conducted at home by physiotherapists, once a week for the first three months, and twice a week at home thereafter, totaling 18 sessions.
Study: 22462558
Drug: Amlodipine/losartan 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/losartan 5 mg/100 mg combination
Study: 20569455
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement containing polyunsaturated fatty acids and Humulus lupulus extract (active group)
Study: 20569455
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement (active group)
Study: 8624233
Drug: Oral-B 35
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral-B 35 toothbrush
Study: 28025309
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure wound therapy (NPWT) using the Prevena NPWT device
Study: 22732468
Drug: Therapeutic vaccine
Normalized name: COVID-19 Therapeutic Vaccine - Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic vaccine
Study: 12894612
Drug: Clonazepam (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam (4 weeks treatment)
Study: 12894612
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 weeks treatment)
Study: 10227808
Drug: Inhaled interleukin-5
Normalized name: interleukin-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled interleukin-5 (IL-5)
Study: 8916983
Drug: Add-back hormone
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Add-back hormone replacement therapy (HRT) with cyclical oestradiol/norgestrol in combination with Zoladex (goserelin acetate)
Study: 8916983
Drug: Combined oestrogen/progestogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oestrogen/progestogen given for 21 months after initial GnRH agonist treatment for 3 months
Study: 3953351
Drug: Intravenous lorcainide
Normalized name: lorcainide
DrugBank: Lorcainide (DB13653)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lorcainide (LOR) 2 mg/kg then 200 mg/24hr
Study: 3953351
Drug: Lidocaine (LID)
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine (LID) 1 mg/kg then 2 mg/min
Study: 24643636
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (180 mg eicosapentaenoic acid and 120 mg docosahexaenoic acid), three times daily for 4 months
Study: 25119571
Drug: Uzara (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uzara (80 mg/8 hours for two doses, then 40 mg/8 hours)
Study: 25119571
Drug: Ibuprofen (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (400 mg/6 hours)
Study: 15847356
Drug: Itopride hydrochloride
Normalized name: Itopride hydrochloride
DrugBank: Itopride (DB04924)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itopride hydrochloride 50mg three times daily for two weeks
Study: 15847356
Drug: Domperidone 10mg
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone 10mg three times daily for two weeks
Study: 1909525
Drug: Safety scores
Normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety scores (pre-inhalation)
Study: 6623361
Drug: Modified amino
Normalized name: LYSYL-PEG-LAUROYL-MODIFIED AMINO ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified amino acid solution rich in branched chains and low in aromatic amino acids and methionine (F080)
Study: 31418598
Drug: C-SSRRMT capsules
Normalized name: chondroitin sulfates Oral Capsule [Optiflex-C]
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-SSRRMT capsules
Study: 31418598
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release market tablets
Study: 22422274
Drug: Oral care
Normalized name: Oral Care Q4 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral care with toothbrushing and 0.12% chlorhexidine digluconate
Study: 22422274
Drug: Oral care
Normalized name: Oral Care Q4 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral care without toothbrushing and 0.12% chlorhexidine digluconate
Study: 18635695
Drug: bupropion XR
Normalized name: bupropion Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupropion XR (150 mg/day, increased to 300 mg/day if inadequate response)
Study: 18635695
Drug: venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: venlafaxine XR (75 mg/day, increased to 150 mg/day if inadequate response)
Study: 17617284
Drug: Topical epinastine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical epinastine hydrochloride ophthalmic solution 0.05% twice daily for 4 days
Study: 17617284
Drug: Systemic loratadine
Normalized name: Loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic loratadine 10 mg once daily for 4 days
Study: 26611782
Drug: Oral metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral metronidazole 500 mg twice daily for 7 days
Study: 17061489
Drug: Oral ampicillin
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ampicillin 2 g for 10 days
Study: 8081076
Drug: Telenzepine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telenzepine 1.5 mg nocte
Study: 8081076
Drug: Telenzepine 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telenzepine 3 mg nocte
Study: 8081076
Drug: Telenzepine 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telenzepine 5 mg nocte
Study: 18398627
Drug: Full dental
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dental treatment
Study: 20111879
Drug: No invasive
Approvals — FDA: no, EMA: no, PMDA: no
Description: No invasive treatment
Study: 20111879
Drug: Other treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other treatment strategies
Study: 12174003
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine administered into the ventrogluteal area
Study: 12174003
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine administered into the anterolateral thigh
Study: 8005300
Drug: RU486 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU486 (1 mg/d for 5 days)
Study: 31899117
Drug: Ultrasonography-guided corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonography-guided corticosteroid injection (CI)
Study: 31899117
Drug: Blind corticosteroid
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blind corticosteroid injection (CI)
Study: 28368486
Drug: Pulsatile GnRH
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulsatile GnRH therapy administered subcutaneously for 3 months
Study: 23298894
Drug: Pulsatile GnRH
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulsatile GnRH therapy
Study: 26637582
Drug: Topical Vitamin
Normalized name: vitamin A Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Vitamin A (VA)
Study: 24026893
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate 1000 mg daily + cholecalciferol 1600 IU daily
Study: 24026893
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate 1000 mg daily
Study: 21566104
Drug: Rituximab (Mabthera,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (Mabthera, 375 mg/m² intravenously) with lower doses of prednisone and calcineurin inhibitors
Study: 21566104
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (current therapy alone)
Study: 16040117
Drug: Position of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Position of the preparation margin
Study: 12548298
Drug: TCP dispersed
Normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCP dispersed in water containing 1200 mg Ca
Study: 12548298
Drug: HCSM containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCSM containing 1200 mg Ca and 65.5 mg Mg
Study: 12548298
Drug: HCSM containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCSM containing 1200 mg Ca and 172 mg Mg
Study: 12548298
Drug: High calcium
Normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High calcium drinks (TCP, HCSM, HCSM+Mg)
Study: 9297766
Drug: Strontium-89 systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strontium-89 systemic radiotherapy (single injection)
Study: 3899046
Drug: Methylphenidate hydrochloride
Normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate hydrochloride (0.15 mg/kg)
Study: 7771914
Drug: Methylphenidate hydrochloride
Normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate hydrochloride (0.3 mg/kg)
Study: 3899046
Drug: Methylphenidate hydrochloride
Normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate hydrochloride (0.6 mg/kg)
Study: 30224584
Drug: Brief Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief Cognitive Behavioral Therapy for Insomnia (CBT-I) consisting of a group session (60 min) and an individual session (30 min)
Study: 26654214
Drug: 11-G vacuum-assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11-G vacuum-assisted biopsy (VAB)
Study: 26654214
Drug: 14-G core
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 14-G core needle biopsy (CNB)
Study: 22898577
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy training alone (PT group)
Study: 22898577
Drug: Both physical
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both physical therapy and Wii Fit training (PW group)
Study: 22898577
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy training (PT group)
Study: 17852170
Drug: Individual cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual cognitive behavioral therapy with attention to relapse prevention
Study: 7743301
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg every morning for 3 weeks)
Study: 2040103
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of prednisone for 14 days
Study: 6165428
Drug: Preparation purified
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation purified by passage twice through a monoclonal antibody affinity chromatography column (NK21F)
Study: 25995489
Drug: Multimodal pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal pain regimen with periarticular injection (PAI)
Study: 24338139
Drug: Milrinone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milrinone (50 μg/kg intravenously followed by 24 hours infusion at 0.5 μg/kg/min)
Study: 17664328
Drug: Zidovudine (ZDV)
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine (ZDV) and Lamivudine (3TC) administered once daily (QD)
Study: 17664328
Drug: Zidovudine (ZDV)
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine (ZDV) and Lamivudine (3TC) administered twice daily (BID)
Study: 2677227
Drug: Highly purified
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly purified pork insulin (Nordisk, Denmark)
Study: 2677227
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin of recombinant DNA origin (Eli Lilly, USA)
Study: 27809613
Drug: Minimal enteral
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal enteral feed (MEF) supplemented with intravenous fluid (IVF), n=52
Study: 24195786
Drug: Imidapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidapril (10 - 20 mg once daily)
Study: 24195786
Drug: Ramipril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (5 - 10 mg once daily)
Study: 19957508
Drug: Combined intercostal
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intercostal nerves block-sevoflurane used inhalation anesthesia with laryngeal mask ventilation
Study: 19957508
Drug: Sevoflurane used
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane used inhalation anesthesia with laryngeal mask ventilation (Control Group)
Study: 15549276
Drug: Cocoa powder
Normalized name: Cocoa powder
DrugBank: Cocoa (DB10977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa powder (11.6 g)
Study: 15549276
Drug: Caffeine (19
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (19 mg) and theobromine (250 mg) combination
Study: 15549276
Drug: Milk chocolate
Normalized name: Meritene Milk Chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk chocolate (methylxanthine doses)
Study: 15549276
Drug: Dark chocolate
Normalized name: Ensure Original Dark Chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dark chocolate (methylxanthine doses)
Study: 11510029
Drug: Gemcitabine (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1,200 mg/m² IV on days 1 and 8) plus Carboplatin (AUC 5 IV on day 1)
Study: 11510029
Drug: Cisplatin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (60 mg/m² IV on day 1) plus Etoposide (120 mg/m² IV on day 1 and 100 mg orally on days 2 and 3)
Study: 11066188
Drug: Empirical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical treatment approaches
Study: 11066188
Drug: Genetic predisposition
Normalized name: Burosumab (genetical recombination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetic predisposition awareness and manipulation of biological pathways
Study: 9001663
Drug: Dexamethasone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.5 mg/kg/day i.v.)
Study: 6394004
Drug: Cefaclor, 250
Normalized name: Cefaclor, 250 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor, 250 mg twice daily for 10 days
Study: 6394004
Drug: Ampicillin, 500
Normalized name: Ampicillin, 500 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin, 500 mg four times daily for 10 days
Study: 22392168
Drug: Sucrose administered
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose administered before heel lance
Study: 20435991
Drug: small-molecule glycoprotein
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: small-molecule glycoprotein IIb/IIIa inhibitors (smGPIs)
Study: 18687841
Drug: Iodine-based solution
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine-based solution preparation for 90 seconds
Study: 18687841
Drug: Clear fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clear fluid antiseptic preparation for 60 seconds
Study: 18687841
Drug: Clear fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clear fluid antiseptic preparation for 90 seconds
Study: 18687841
Drug: Iodine-based solution
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine-based solution preparation for 60 seconds
Study: 30454876
Drug: Agent support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agent support
Study: 29869004
Drug: Intramuscular supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular supplementation of vitamin D with a single dose of 600,000 IU cholecalciferol
Study: 29869004
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (oral supplementation limited to 1400 IU of vitamin D)
Study: 27160498
Drug: Integrated nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated nutritional therapy (oral, enteral, and parenteral)
Study: 10953902
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (20 g/day for 5 days to 3 g/day for 9 weeks)
Study: 9105072
Drug: Surfactant (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant (up to four doses of 100 mg phospholipids/kg)
Study: 1337163
Drug: Low calcium
Normalized name: Dianeal Low Calcium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low calcium PD fluid (calcium 1.25 mmol/l) with oral calcium carbonate
Study: 1337163
Drug: Standard PD
Normalized name: PD-0299685
DrugBank: PD-0299685 (DB15264)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard PD solution (calcium 1.75 mmol/l) with calcium carbonate plus aluminium hydroxide phosphate binders
Study: 1337163
Drug: Low calcium
Normalized name: Dianeal Low Calcium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low calcium PD fluid (calcium 1.25 mmol/l)
Study: 1337163
Drug: Standard PD
Normalized name: PD-0299685
DrugBank: PD-0299685 (DB15264)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard PD solution (calcium 1.75 mmol/l)
Study: 2435043
Drug: Oral phenoxybenzamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral phenoxybenzamine (10 mg b.i.d.; n = 21)
Study: 2435043
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets (n = 22)
Study: 29634086
Drug: Multilevel cardiovascular
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multilevel cardiovascular disease prevention program (6 months, twice-weekly exercise, nutrition, and heart health classes)
Study: 27792801
Drug: Methacrylate-based composite
Normalized name: methacrylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methacrylate-based composite resin (Filtek Z250) with oxalic acid-based desensitizing agent (Desenssiv, SSWhite)
Study: 27792801
Drug: Silorane-based composite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silorane-based composite resin (Silorane P90) with oxalic acid-based desensitizing agent (Desenssiv, SSWhite)
Study: 15696400
Drug: Sotalol (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol (1.5 mg/kg)
Study: 6617715
Drug: Flecainide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide (2 mg/kg)
Study: 12889588
Drug: Metronidazole treatment
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole treatment for trichomoniasis
Study: 12889588
Drug: Metronidazole treatment
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole treatment for bacterial vaginosis
Study: 31512143
Drug: TurboCBD™ 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: TurboCBD™ 90 mg
Study: 31512143
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg control
Study: 21899812
Drug: Salicylic acid
Normalized name: Salicylic Acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salicylic acid (50% self-treatment)